Clinical Trials Logo

Clinical Trial Summary

Understand the effect of recombinant EPO (rEPO) boosting and microdosing on the hematological module of the Athlete Biological Passport (ABP) - Measure the change in CD71 longitudinally in subjects from both cohorts - Assess whether rEPO administration can be detected in a dried blood spot (DBS) using recent advances in analytical methodologies - Compare windows of rEPO detection using both Athlete Biological Passport models and direct detection using analytical methods in urine, blood, and DBS


Clinical Trial Description

Despite being banned by the World Anti-Doping Agency, blood doping is a common method of performance enhancement used by athletes wishing to gain an unfair advantage over their competition. A common way to achieve this increase is by using erythropoiesis stimulating agents (ESA's), namely recombinant erythropoietin (rEPO). Though laboratory tests have been developed for the direct detection of all known isoforms of exogenously administered ESAs in both urine and blood, athletes have found ways to circumvent these testing measures using techniques such as microdosing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04073849
Study type Interventional
Source Sports Medicine Research and Testing Laboratory
Contact
Status Completed
Phase Early Phase 1
Start date July 15, 2019
Completion date December 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT02370368 - Comparison of Videogame Based Dance Training With Agility Ladder Drills on Agility of Volleyball Players N/A
Terminated NCT03915535 - Impact of Fish Oil Monoglycerides on the Modulation of Mitochondrial Functions and Lactate Threshold Phase 4
Completed NCT03209596 - Orange Juice Supplementation in Soccer Players N/A
Completed NCT04444388 - Effect of Cocoa Supplementation in Training Athletes Microbiota and Metabolome N/A
Recruiting NCT05574322 - Efficacy of a Foot Strengthening Protocol on Sport Performance Kinetics N/A